IL191913D0 - Pneumococcal polysaccharide conjugate vaccine - Google Patents

Pneumococcal polysaccharide conjugate vaccine

Info

Publication number
IL191913D0
IL191913D0 IL19191308A IL19191308A IL191913D0 IL 191913 D0 IL191913 D0 IL 191913D0 IL 19191308 A IL19191308 A IL 19191308A IL 19191308 A IL19191308 A IL 19191308A IL 191913 D0 IL191913 D0 IL 191913D0
Authority
IL
Israel
Prior art keywords
conjugate vaccine
polysaccharide conjugate
pneumococcal polysaccharide
pneumococcal
vaccine
Prior art date
Application number
IL19191308A
Other versions
IL191913A (en
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
Priority to GB0526232A priority Critical patent/GB0526232D0/en
Priority to GB0607087A priority patent/GB0607087D0/en
Priority to GBGB0607088.2A priority patent/GB0607088D0/en
Priority to GB0609902A priority patent/GB0609902D0/en
Priority to GBGB0620336.8A priority patent/GB0620336D0/en
Priority to GB0620337A priority patent/GB0620337D0/en
Priority to GB0620815A priority patent/GB0620815D0/en
Priority to GB0620816A priority patent/GB0620816D0/en
Priority to PCT/GB2006/004634 priority patent/WO2007068907A2/en
Priority to PCT/EP2006/069974 priority patent/WO2007071707A2/en
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of IL191913D0 publication Critical patent/IL191913D0/en
Publication of IL191913A publication Critical patent/IL191913A/en
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39133667&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL191913(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/385Haptens or antigens, bound to carriers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/09Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092Streptococcus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/55Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55566Emulsions, e.g. Freund's adjuvant, MF59
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/57Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031Proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031Proteins
    • A61K2039/6037Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031Proteins
    • A61K2039/6068Other bacterial proteins, e.g. OMP
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6087Polysaccharides; Lipopolysaccharides [LPS]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/62Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/62Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/70Multivalent vaccine
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y02A50/38Medical treatment of vector-borne diseases characterised by the agent
    • Y02A50/408Medical treatment of vector-borne diseases characterised by the agent the vector-borne disease being caused by a protozoa
    • Y02A50/411Medical treatment of vector-borne diseases characterised by the agent the vector-borne disease being caused by a protozoa of the genus Plasmodium, i.e. Malaria
    • Y02A50/412Medical treatment of vector-borne diseases characterised by the agent the vector-borne disease being caused by a protozoa of the genus Plasmodium, i.e. Malaria the medicinal preparation containing antigens or antibodies, e.g. vaccines, antisera
IL19191308A 2005-12-13 2008-06-03 Streptococcus pneumoniae immunogenic composition comprising s. pneumoniae capsular saccharides conjugated to carrier proteins and its use in the manufacture of a medicament for treating diseases caused by s. pneumoniae infection IL191913A (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
GB0526232A GB0526232D0 (en) 2005-12-22 2005-12-22 Vaccine
GB0607087A GB0607087D0 (en) 2006-04-07 2006-04-07 Vaccine
GBGB0607088.2A GB0607088D0 (en) 2006-04-07 2006-04-07 Vaccine
GB0609902A GB0609902D0 (en) 2006-05-18 2006-05-18 Novel composition
GB0620337A GB0620337D0 (en) 2006-10-12 2006-10-12 Vaccine
GBGB0620336.8A GB0620336D0 (en) 2006-10-12 2006-10-12 Vaccine
GB0620815A GB0620815D0 (en) 2006-10-19 2006-10-19 Vaccine
GB0620816A GB0620816D0 (en) 2006-10-19 2006-10-19 vaccine
PCT/GB2006/004634 WO2007068907A2 (en) 2005-12-13 2006-12-12 Vaccine compositions comprising a saponin adjuvant
PCT/EP2006/069974 WO2007071707A2 (en) 2005-12-22 2006-12-20 Pneumococcal polysaccharide conjugate vaccine

Publications (2)

Publication Number Publication Date
IL191913D0 true IL191913D0 (en) 2009-02-11
IL191913A IL191913A (en) 2012-07-31

Family

ID=39133667

Family Applications (5)

Application Number Title Priority Date Filing Date
IL191911A IL191911A (en) 2005-12-13 2008-06-03 Immunogenic composition comprising s. pneumoniae capsular saccharide conjugates and various aspects related thereto
IL19191308A IL191913A (en) 2005-12-13 2008-06-03 Streptococcus pneumoniae immunogenic composition comprising s. pneumoniae capsular saccharides conjugated to carrier proteins and its use in the manufacture of a medicament for treating diseases caused by s. pneumoniae infection
IL19208408A IL192084A (en) 2005-12-13 2008-06-12 Immunogenic composition for infants comprising a multivalent streptococcus pneumoniae vaccine and its use
IL21166411A IL211664D0 (en) 2005-12-13 2011-03-10 Streptococcus pnevmoniae immunogenic
IL219641A IL219641A (en) 2005-12-13 2012-05-08 Immunogenic composition comprising at least four s.pneumoniae capsular saccharide conjugates containing saccharides from different s.pneumoniae serotypes and various aspects related thereto

Family Applications Before (1)

Application Number Title Priority Date Filing Date
IL191911A IL191911A (en) 2005-12-13 2008-06-03 Immunogenic composition comprising s. pneumoniae capsular saccharide conjugates and various aspects related thereto

Family Applications After (3)

Application Number Title Priority Date Filing Date
IL19208408A IL192084A (en) 2005-12-13 2008-06-12 Immunogenic composition for infants comprising a multivalent streptococcus pneumoniae vaccine and its use
IL21166411A IL211664D0 (en) 2005-12-13 2011-03-10 Streptococcus pnevmoniae immunogenic
IL219641A IL219641A (en) 2005-12-13 2012-05-08 Immunogenic composition comprising at least four s.pneumoniae capsular saccharide conjugates containing saccharides from different s.pneumoniae serotypes and various aspects related thereto

Country Status (37)

Country Link
US (9) US20090017072A1 (en)
EP (10) EP1973564B1 (en)
JP (7) JP5792920B2 (en)
KR (4) KR101367237B1 (en)
CN (6) CN110179974A (en)
AR (3) AR058592A1 (en)
AT (1) AT520415T (en)
AU (4) AU2006327041B2 (en)
BR (3) BRPI0620163B1 (en)
CA (5) CA2808919C (en)
CL (1) CL2013002106A1 (en)
CR (2) CR10119A (en)
CY (4) CY1112677T1 (en)
DK (5) DK1973564T3 (en)
EA (3) EA014107B1 (en)
ES (4) ES2630759T3 (en)
HK (1) HK1120230A1 (en)
HR (4) HRP20110685T1 (en)
HU (3) HUE041979T2 (en)
IL (5) IL191911A (en)
JO (1) JO2813B1 (en)
LT (3) LT2384765T (en)
MA (3) MA30065B1 (en)
MX (2) MX354843B (en)
MY (4) MY160199A (en)
NO (3) NO344187B1 (en)
NZ (4) NZ569076A (en)
PE (2) PE20071058A1 (en)
PH (1) PH12014502544A1 (en)
PL (4) PL3017827T3 (en)
PT (5) PT1962899E (en)
SG (1) SG168517A1 (en)
SI (5) SI3017827T1 (en)
TR (1) TR201900418T4 (en)
TW (4) TWI487534B (en)
UA (2) UA96934C2 (en)
WO (3) WO2007071711A2 (en)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA006313B1 (en) * 2000-06-29 2005-10-27 Глаксосмитклайн Байолоджикалс С.А. Multi-valent immunogenic compositions and methods for using same
AU2002214861B2 (en) * 2000-11-07 2006-09-28 Immunovaccine Technologies Inc. Vaccines with enhanced immune response and methods for their preparation
US7955605B2 (en) 2005-04-08 2011-06-07 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
EA012528B1 (en) 2005-06-27 2009-10-30 Глаксосмитклайн Байолоджикалс С.А. Immunogenic composition
HUE041979T2 (en) 2005-12-22 2019-06-28 Glaxosmithkline Biologicals Sa Pneumococcal polysaccharide conjugate vaccine
US20110002962A1 (en) * 2006-08-17 2011-01-06 The Uab Research Foundation Immunogenic PcpA Polypeptides and Uses Thereof
EP2155244B1 (en) * 2007-04-23 2017-03-22 Serum Institute of India Private Limited Antigenic polysaccharides and process for their preparation
UY31064A1 (en) 2007-05-02 2009-01-05 Glaxosmithkline Biolog Sa Vaccine
SI2167121T1 (en) * 2007-06-26 2015-12-31 Glaxosmithkline Biologicals S.A. Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
ES2588705T3 (en) 2007-09-27 2016-11-04 Immunovaccine Technologies Inc. Use of liposomes in a vehicle comprising a continuous hydrophobic phase for delivery of polynucleotides in vivo
US20100285069A1 (en) 2007-10-19 2010-11-11 Mario Contorni Meningococcal vaccine formulations
US8226959B2 (en) 2008-02-01 2012-07-24 Newcastle Innovation Pty Ltd Vaccine compositions
JP2011516597A (en) * 2008-04-16 2011-05-26 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム Vaccine
AU2009237647A1 (en) * 2008-04-16 2009-10-22 Glaxosmithkline Biologicals S.A. Vaccine
WO2009143413A1 (en) * 2008-05-22 2009-11-26 Children'smedical Center Corporation Synergistic immunogenic fusion protein-polysaccharide conjugate
GB0822634D0 (en) 2008-12-11 2009-01-21 Novartis Ag Meningitis vaccines
GB0822633D0 (en) 2008-12-11 2009-01-21 Novartis Ag Formulation
NZ593674A (en) 2008-12-17 2013-03-28 Novartis Ag Meningococcal vaccines including hemoglobin receptor
JP5806204B2 (en) * 2009-03-24 2015-11-10 ノバルティス アーゲー Combination containing pneumococcal serotype 14 sugar
EP2411045A1 (en) * 2009-03-24 2012-02-01 Novartis AG Combinations of meningococcal factor h binding protein and pneumococcal saccharide conjugates
NZ595234A (en) 2009-03-24 2013-12-20 Novartis Ag Adjuvanting meningococcal factor h binding protein
EP2424562B1 (en) * 2009-04-30 2015-10-07 Coley Pharmaceutical Group, Inc. Pneumococcal vaccine and uses thereof
WO2010141312A2 (en) 2009-06-01 2010-12-09 Wake Forest University Health Sciences Flagellin fusion proteins and conjugates comprising pneumococcus antigens and methods of using the same
US20120237536A1 (en) 2009-09-10 2012-09-20 Novartis Combination vaccines against respiratory tract diseases
KR20110068831A (en) * 2009-12-16 2011-06-22 재단법인 전라남도생물산업진흥재단 A liposomal composition, a process for the preparation thereof, and a use thereof as a pneumococcal vaccine
TW201136603A (en) * 2010-02-09 2011-11-01 Merck Sharp & Amp Dohme Corp 15-valent pneumococcal polysaccharide-protein conjugate vaccine composition
GB201003922D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Conjugation process
GB201003924D0 (en) * 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Immunogenic composition
US10478483B2 (en) 2010-06-25 2019-11-19 Glaxosmithkline Biologicals Sa Combinations of meningococcal factor H binding proteins
CA2810971A1 (en) 2010-09-10 2012-03-15 Novartis Ag Developments in meningococcal outer membrane vesicles
WO2012072769A1 (en) 2010-12-01 2012-06-07 Novartis Ag Pneumococcal rrgb epitopes and clade combinations
KR20140026392A (en) * 2011-03-02 2014-03-05 노파르티스 아게 Combination vaccines with lower doses of antigen and/or adjuvant
GB201103836D0 (en) * 2011-03-07 2011-04-20 Glaxosmithkline Biolog Sa Conjugation process
BR112013029514A2 (en) * 2011-05-17 2019-09-24 Glaxosmithkline Biologicals Sa immunogenic composition, vaccine, and method of treating or preventing a disease
CA2850857A1 (en) 2011-10-06 2013-04-11 Immunovaccine Technologies Inc. Liposome compositions comprising an adjuvant that activates or increases the activity of tlr2 and uses thereof
US20150209419A1 (en) 2011-12-29 2015-07-30 Beatrice Maria Arico Adjuvanted combinations of meningococcal factor h binding proteins
EP2809349B1 (en) * 2012-01-30 2018-12-19 Serum Institute Of India Private Limited Immunogenic composition
EP2809785B1 (en) 2012-02-02 2017-11-01 GlaxoSmithKline Biologicals SA Promoters for increased protein expression in meningococcus
US20150132339A1 (en) * 2012-03-07 2015-05-14 Novartis Ag Adjuvanted formulations of streptococcus pneumoniae antigens
CN104159603A (en) 2012-03-08 2014-11-19 诺华股份有限公司 Combination vaccines with tlr4 agonists
KR20130142574A (en) 2012-06-20 2013-12-30 에스케이케미칼주식회사 Multivalent pneumococcal polysaccharide-protein conjugate composition
RU2510281C2 (en) * 2012-06-22 2014-03-27 Общество с ограниченной ответственностью "Эпитоп" (ООО "Эпитоп") HYBRID PROTEIN VACCINE AGAINST PNEUMONIA CAUSED BY Streptococcus pneumoniae
CN104487086B (en) * 2012-07-07 2019-08-30 巴拉特生物技术国际有限公司 Non-animal derived nonalcoholic vaccine composition and preparation method thereof
HUE041381T2 (en) * 2012-08-16 2019-05-28 Pfizer Glycoconjugation processes and compositions
WO2014037472A1 (en) 2012-09-06 2014-03-13 Novartis Ag Combination vaccines with serogroup b meningococcus and d/t/p
GB201218660D0 (en) 2012-10-17 2012-11-28 Glaxosmithkline Biolog Sa Immunogenic composition
KR20140075196A (en) * 2012-12-11 2014-06-19 에스케이케미칼주식회사 Multivalent pneumococcal polysaccharide-protein conjugate composition
KR20140075201A (en) * 2012-12-11 2014-06-19 에스케이케미칼주식회사 Multivalent pneumococcal polysaccharide-protein conjugate composition
CA2894260A1 (en) 2012-12-18 2014-06-26 Glaxosmithkline Biologicals S.A. Conjugates for protecting against diphtheria and/or tetanus
RU2544168C1 (en) * 2014-01-17 2015-03-10 Андрей Дмитриевич Протасов Method for forming immunological memory to streptococcus pneumoniae antigens in patients with chronic obstructive pulmonary disease
SG10201803187VA (en) * 2014-01-21 2018-05-30 Pfizer Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
RU2688831C2 (en) * 2014-01-21 2019-05-22 Пфайзер Инк. Streptococcus pneumoniae capsular polysaccharides and conjugates thereof
JP2017505792A (en) * 2014-02-14 2017-02-23 ファイザー・インク Immunogenic glycoprotein conjugates
CN103893751B (en) * 2014-03-26 2016-04-20 天津康希诺生物技术有限公司 A kind of pneumococal polysaccharide Protein Conjugation vaccine and preparation method thereof
CN103936842B (en) * 2014-04-30 2016-03-23 重庆医科大学 Application of pneumolysin mutants and their use as a mucosal immunoadjuvant
US9107906B1 (en) 2014-10-28 2015-08-18 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
RU2600838C1 (en) * 2015-06-08 2016-10-27 Андрей Дмитриевич Протасов Method of enhancing nonspecific protection factors activity in patients with chronic obstructive pulmonary disease
KR20160146240A (en) 2015-06-12 2016-12-21 전관구 Manufacturing process of silver oxide nanoparticle and silver nanoparticle
TW201822814A (en) * 2015-07-21 2018-07-01 美商輝瑞股份有限公司 Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
GB201518684D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Vaccine
GB201522068D0 (en) * 2015-12-15 2016-01-27 Glaxosmithkline Biolog Sa Dried composition
CA3031797A1 (en) * 2016-08-05 2018-02-08 Sanofi Pasteur, Inc. Multivalent pneumococcal polysaccharide-protein conjugate composition
EA201990838A1 (en) 2016-09-30 2019-08-30 Байолоджикал И Лимитед Compositions of a polyvalent pneumococcus vaccine containing polysaccharide-protein conjugates
WO2018080213A1 (en) * 2016-10-28 2018-05-03 주식회사 엘지화학 Multivalent immunogenic composition having increased igg titer, and use thereof
CN108144052A (en) * 2016-12-02 2018-06-12 武汉博沃生物科技有限公司 Streptococcus pneumoniae polysaccharides-protein conjugate and its preparation method and purposes
CA3050622A1 (en) * 2017-01-20 2018-07-26 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
CN110225757A (en) * 2017-01-31 2019-09-10 默沙东公司 By the method for S. pneumoniae serotypes 19F production capsular polysaccharide protein conjugate
WO2018144799A1 (en) * 2017-02-03 2018-08-09 SCHADECK, Eva, Barbara Haemophilus influenzae saccharide-carrier conjugate compositions and uses thereof
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
CN107929728A (en) * 2017-04-19 2018-04-20 武汉博沃生物科技有限公司 A kind of pneumoprotein vaccine and preparation method thereof
WO2019043245A1 (en) * 2017-09-04 2019-03-07 London School Of Hygiene And Tropical Medicine Microbial cells expressing streptococcal serotypes
WO2019050818A1 (en) * 2017-09-07 2019-03-14 Merck Sharp & Dohme Corp. Processes for the formulation of pneumococcal polysaccharides for conjugation to a carrier protein
CN108524926A (en) * 2018-06-29 2018-09-14 康希诺生物股份公司 A kind of formulation compositions of multivalent pneumococcal combined vaccine and its application

Family Cites Families (177)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4057685A (en) 1972-02-02 1977-11-08 Abbott Laboratories Chemically modified endotoxin immunizing agent
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
EP0027888B1 (en) 1979-09-21 1986-04-16 Hitachi, Ltd. Semiconductor switch
BE889979A (en) 1981-08-14 1982-02-15 Smith Kline Rit polysaccharide preparation Method bacterial capsular antigenic purified, obtained products and their use
US4673574A (en) 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
US4619828A (en) 1982-07-06 1986-10-28 Connaught Laboratories, Inc. Polysaccharide exotoxoid conjugate vaccines
SE8205892D0 (en) 1982-10-18 1982-10-18 Bror Morein Immunogenic membrane protein complex, seen for the front up and tell priority over derav as immune stimulant and as vaccine
US4459286A (en) 1983-01-31 1984-07-10 Merck & Co., Inc. Coupled H. influenzae type B vaccine
US4695624A (en) 1984-05-10 1987-09-22 Merck & Co., Inc. Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency
US4808700A (en) 1984-07-09 1989-02-28 Praxis Biologics, Inc. Immunogenic conjugates of non-toxic E. coli LT-B enterotoxin subunit and capsular polymers
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4709017A (en) 1985-06-07 1987-11-24 President And Fellows Of Harvard College Modified toxic vaccines
IT1187753B (en) 1985-07-05 1987-12-23 Sclavo Spa Glycoprotein conjugate to attivita 'trivalent immunogenic
US5173294A (en) 1986-11-18 1992-12-22 Research Foundation Of State University Of New York Dna probe for the identification of haemophilus influenzae
US4950740A (en) 1987-03-17 1990-08-21 Cetus Corporation Recombinant diphtheria vaccines
EP0362278A4 (en) 1987-06-05 1990-05-14 Us Health Autocrine motility factors in cancer diagnosis and management.
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4940460A (en) 1987-06-19 1990-07-10 Bioject, Inc. Patient-fillable and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US5785973A (en) * 1988-02-01 1998-07-28 Praxis Biologics, Inc. Synthetic peptides representing a T-cell epitope as a carrier molecule for conjugate vaccines
US5339163A (en) 1988-03-16 1994-08-16 Canon Kabushiki Kaisha Automatic exposure control device using plural image plane detection areas
US5278302A (en) 1988-05-26 1994-01-11 University Patents, Inc. Polynucleotide phosphorodithioates
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
DE3841091A1 (en) 1988-12-07 1990-06-13 Behringwerke Ag Synthetic antigenic, process for their production and their use
AU626961B2 (en) * 1988-12-16 1992-08-13 De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezonheid En Cultuur Pneumolysin mutants and pneumococcal vaccines made therefrom
DE68907045D1 (en) 1989-01-17 1993-07-15 Eniricerche Spa Synthetic peptides and their use as a general carrier for the preparation of immunogenic conjugates that are suitable for the development of synthetic vaccines.
EP0382271B1 (en) 1989-02-04 1994-12-21 Akzo Nobel N.V. Tocols as adjuvant in vaccine
CA2017507C (en) 1989-05-25 1996-11-12 Gary Van Nest Adjuvant formulation comprising a submicron oil droplet emulsion
FR2649012B1 (en) 1989-07-03 1991-10-25 Seppic Sa injecting multiphase emulsions
FR2649013B1 (en) 1989-07-03 1991-10-25 Seppic Sa Vaccines and fluids active principles of vectors containing a metabolizable oil
AU651949B2 (en) 1989-07-14 1994-08-11 American Cyanamid Company Cytokine and hormone carriers for conjugate vaccines
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
IT1237764B (en) 1989-11-10 1993-06-17 Eniricerche Spa Synthetic peptides useful as universal carriers for the preparation of immunogenic conjugates and their use for the development of synthetic vaccines.
SE466259B (en) 1990-05-31 1992-01-20 Arne Forsgren Protein D - an IgD-binding protein FROM Haemophilus influenzae, and anvaendning this Foer analysis, vaccines and uppreningsaendamaal
EP0468520A3 (en) 1990-07-27 1992-07-01 Mitsui Toatsu Chemicals, Inc. Immunostimulatory remedies containing palindromic dna sequences
IL98715D0 (en) 1990-08-13 1992-07-15 American Cyanamid Co Filamentous hemaglutinin of bodetella pertussis as a carrier molecule for conjugate vaccines
US5153312A (en) 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
CA2059692C (en) 1991-01-28 2004-11-16 Peter J. Kniskern Pneumoccoccal polysaccharide conjugate vaccine
CA2059693C (en) * 1991-01-28 2003-08-19 Peter J. Kniskern Polysaccharide antigens from streptococcus pneumoniae
ES2118812T3 (en) 1991-02-15 1998-10-01 Uab Research Foundation Pneumococcal protein structural gene.
US5476929A (en) 1991-02-15 1995-12-19 Uab Research Foundation Structural gene of pneumococcal protein
US6592876B1 (en) 1993-04-20 2003-07-15 Uab Research Foundation Pneumococcal genes, portions thereof, expression products therefrom, and uses of such genes, portions and products
GB9105992D0 (en) 1991-03-21 1991-05-08 Smithkline Beecham Biolog Vaccine
US5552146A (en) 1991-08-15 1996-09-03 Board Of Regents, The University Of Texas System Methods and compositions relating to useful antigens of Moraxella catarrhalis
GB9118204D0 (en) 1991-08-23 1991-10-09 Weston Terence E Needle-less injector
WO1993015760A1 (en) 1992-02-11 1993-08-19 U.S. Government, As Represented By The Secretary Of The Army Dual carrier immunogenic construct
IT1262896B (en) 1992-03-06 1996-07-22 Compounds conjugates formed by heat shock proteins (hsp) poly- and oligo-saccharides, their use for the production of vaccines.
MA22842A1 (en) 1992-03-27 1993-10-01 Smithkline Beecham Biolog Process for the preparation of vaccine compositions.
DE69324487D1 (en) 1992-05-06 1999-05-20 Harvard College Receptor binding region of diphtherietoxius
JP3428646B2 (en) 1992-06-18 2003-07-22 プレジデント アンド フェローズ オブ ハーバードカレッジ Diphtheria toxin vaccine
DK0671948T3 (en) 1992-06-25 1997-09-01 Smithkline Beecham Biolog A vaccine composition containing adjuvants
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
IL102687A (en) 1992-07-30 1997-06-10 Yeda Res & Dev Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them
US5569189A (en) 1992-09-28 1996-10-29 Equidyne Systems, Inc. hypodermic jet injector
US5334144A (en) 1992-10-30 1994-08-02 Becton, Dickinson And Company Single use disposable needleless injector
GB9224584D0 (en) 1992-11-23 1993-01-13 Connaught Lab Use of outer membrane protein d15 and its peptides as vaccine against haempohilus influenzae diseases
DK0812593T4 (en) 1993-03-23 2008-05-13 Smithkline Beecham Biolog Vaccine preparations containing 3-O-deacylated monophosphoryl lipid-A
JP3429313B2 (en) 1993-05-18 2003-07-22 オハイオ・ステイト・リサーチ・ファウンデーション Otitis media vaccine
CA2215933C (en) * 1995-03-22 2009-10-13 Andrew Lees Producing immunogenic constructs using soluble carbohydrates activated via organic cyanylating reagents
ES2210262T3 (en) 1993-09-22 2004-07-01 Henry M. Jackson Foundation For The Advancement Of Military Medicine Procedure for activating a soluble glucido with the help of new cianilantes reagents to produce immunogenic structures.
US6005099A (en) 1993-11-17 1999-12-21 Laboratoires Om S.A. Glucosamine disaccharides, method for their preparation, pharmaceutical composition comprising same, and their use
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
WO1995024176A1 (en) 1994-03-07 1995-09-14 Bioject, Inc. Ampule filling device
US5466220A (en) 1994-03-08 1995-11-14 Bioject, Inc. Drug vial mixing and transfer device
WO1995026204A1 (en) 1994-03-25 1995-10-05 Isis Pharmaceuticals, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
US6455673B1 (en) 1994-06-08 2002-09-24 President And Fellows Of Harvard College Multi-mutant diphtheria toxin vaccines
US5917017A (en) 1994-06-08 1999-06-29 President And Fellows Of Harvard College Diphtheria toxin vaccines bearing a mutated R domain
WO1996002555A1 (en) 1994-07-15 1996-02-01 The University Of Iowa Research Foundation Immunomodulatory oligonucleotides
US5565204A (en) 1994-08-24 1996-10-15 American Cyanamid Company Pneumococcal polysaccharide-recombinant pneumolysin conjugate vaccines for immunization against pneumococcal infections
US5599302A (en) 1995-01-09 1997-02-04 Medi-Ject Corporation Medical injection system and method, gas spring thereof and launching device using gas spring
CA2217178C (en) 1995-04-25 2009-09-29 Smithkline Beecham Biologicals S.A. Vaccines containing a saponin and a sterol
US6440425B1 (en) 1995-05-01 2002-08-27 Aventis Pasteur Limited High molecular weight major outer membrane protein of moraxella
US5843464A (en) 1995-06-02 1998-12-01 The Ohio State University Synthetic chimeric fimbrin peptides
US5695768A (en) * 1995-06-07 1997-12-09 Alberta Research Council Immunostimulating activity of Streptococcus pneumoniae serotype 8 oligosaccharides
GB9513074D0 (en) 1995-06-27 1995-08-30 Cortecs Ltd Novel anigen
US5666153A (en) 1995-10-03 1997-09-09 Virtual Shopping, Inc. Retractable teleconferencing apparatus
US5730723A (en) 1995-10-10 1998-03-24 Visionary Medical Products Corporation, Inc. Gas pressured needle-less injection device and method
US6290970B1 (en) 1995-10-11 2001-09-18 Aventis Pasteur Limited Transferrin receptor protein of Moraxella
US5893397A (en) 1996-01-12 1999-04-13 Bioject Inc. Medication vial/syringe liquid-transfer apparatus
US6090576A (en) 1996-03-08 2000-07-18 Connaught Laboratories Limited DNA encoding a transferrin receptor of Moraxella
GB9607549D0 (en) 1996-04-11 1996-06-12 Weston Medical Ltd Spring-powered dispensing device
WO1997041151A2 (en) 1996-05-01 1997-11-06 The Rockefeller University Choline binding proteins for anti-pneumococcal vaccines
US7341727B1 (en) 1996-05-03 2008-03-11 Emergent Product Development Gaithersburg Inc. M. catarrhalis outer membrane protein-106 polypeptide, methods of eliciting an immune response comprising same
JP4012252B2 (en) 1996-06-18 2007-11-21 アルザ コーポレイション Device for enhancing transdermal release or sampling of drugs
EP0956289A4 (en) 1996-08-16 2004-10-13 Smithkline Beecham Corp Novel prokaryotic polynucleotides, polypeptides and their uses
GB9620795D0 (en) 1996-10-05 1996-11-20 Smithkline Beecham Plc Vaccines
PT942983E (en) 1996-10-31 2007-02-28 Human Genome Sciences Inc Streptococcus pneumoniae antigens and vaccines
JP2002503087A (en) 1996-11-12 2002-01-29 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ c3-binding proteins of Streptococcus pneumoniae
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
ES2195190T3 (en) 1996-12-20 2003-12-01 Alza Corp Device and method to improve transdermal agent flux.
DE19708537A1 (en) 1997-03-03 1998-09-10 Biotechnolog Forschung Gmbh Novel surface protein (SpsA protein) of Streptococcus pneumoniae etc.
US6299881B1 (en) 1997-03-24 2001-10-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts
US6303347B1 (en) 1997-05-08 2001-10-16 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US6764840B2 (en) 1997-05-08 2004-07-20 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
FR2763244B1 (en) * 1997-05-14 2003-08-01 Pasteur Merieux Serums Vacc multivalent vaccine composition is mixed carrier
US5993412A (en) 1997-05-19 1999-11-30 Bioject, Inc. Injection apparatus
WO1998055606A2 (en) 1997-06-03 1998-12-10 Connaught Laboratories Limited Lactoferrin receptor genes of moraxella
GB9711990D0 (en) 1997-06-11 1997-08-06 Smithkline Beecham Biolog Vaccine
GB9713156D0 (en) 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
EP0998557A2 (en) 1997-07-21 2000-05-10 North American Vaccine, Inc. Modified immunogenic pneumolysin, compositions and their use as vaccines
GB9718901D0 (en) 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
ES2201551T3 (en) 1997-09-05 2004-03-16 Glaxosmithkline Biologicals S.A. Oil in water emulsions containing saponins.
US6224880B1 (en) * 1997-09-24 2001-05-01 Merck & Co., Inc. Immunization against Streptococcus pneumoniae using conjugated and unconjugated pneumoccocal polysaccharide vaccines
AU9510598A (en) 1997-09-24 1999-04-12 American Cyanamid Company Human complement c3-degrading proteinase from (streptococcus pneumoniae)
US5965714A (en) * 1997-10-02 1999-10-12 Connaught Laboratories, Inc. Method for the covalent attachment of polysaccharides to protein molecules
AU756828B2 (en) 1997-12-02 2003-01-23 Powderject Vaccines, Inc. Transdermal delivery of particulate vaccine compositions
IT1298087B1 (en) 1998-01-08 1999-12-20 Fiderm S R L A device for controlling the depth 'of penetration of a needle, in particular applicable to a syringe for injections
US7018637B2 (en) 1998-02-23 2006-03-28 Aventis Pasteur, Inc Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines
DE69942176D1 (en) 1998-04-07 2010-05-06 Medimmune Llc Choline-binding protein derivatives from pneumocokes as a vaccine
HU0102306A3 (en) 1998-04-07 2008-04-28 St Jude Childrens Res Hospital A polypeptide comprising the amino acid of an n-terminal choline binding protein a truncate, vaccine derived therefrom and uses thereof
CA2328399A1 (en) 1998-04-23 1999-10-28 University Of Alabama At Birmingham Pneumococcal surface protein c(pspc), epitopic regions and strain selection thereof, and uses therefor
AU7924598A (en) 1998-06-08 1999-12-30 Sca Emballage France Fast flattening packaging
GB9812613D0 (en) 1998-06-11 1998-08-12 Smithkline Beecham Biolog Vaccine
DE69935330T2 (en) 1998-06-30 2007-10-31 Om Pharma New acylated pseudodipeptides, method for the production thereof and pharmaceutical compositions containing thereof
HU0103100A3 (en) 1998-08-19 2005-11-28 Baxter Healthcare Sa Immunogenic betha-propionamido-linked polysaccharide protein conjugate useful as a vaccine produced using an n-acryloylated polysaccharide
GB9818548D0 (en) 1998-08-25 1998-10-21 Microbiological Res Authority Treatment of mucas hypersecretion
CN1352691A (en) 1998-09-24 2002-06-05 美国明尼苏达州大学 Human complement C3-degrading polypeptide from i(streptococcus pneumoniae)
US6541616B1 (en) 1998-10-01 2003-04-01 Antex Biologics Inc. Moraxella catarrhalis protein, gene sequence and uses thereof
AU750587B2 (en) 1998-10-16 2002-07-25 Smithkline Beecham Biologicals (Sa) Adjuvant systems and vaccines
WO2000030299A1 (en) 1998-11-17 2000-05-25 Schlumberger Technology Corporation Transmitting information over a communication link
AU2027400A (en) 1998-11-19 2000-06-05 St. Jude Children's Research Hospital Identification and characterization of novel pneumococcal choline binding proteins, cbpg and cbpd, and diagnostic and therapeutic uses thereof
JP4689044B2 (en) 1998-12-21 2011-05-25 メディミューン,インコーポレーテッド Streptococcus pneumoniae proteins and immunogenic fragments for vaccine use
KR101170203B1 (en) 1998-12-23 2012-07-31 아이디 바이오메디칼 코포레이션 Novel Streptococcus antigens
EP1034792A1 (en) 1999-03-11 2000-09-13 Ingileif Jonsdottir Intranasal delivery of pneumococcal polysaccharide vaccines
EP1880735A3 (en) 1999-03-19 2008-03-12 GlaxoSmithKline Biologicals S.A. Vaccine
CA2365914A1 (en) 1999-04-09 2000-10-19 Techlab, Inc. Recombinant clostridium toxin a protein carrier for polysaccharide conjugate vaccines
CA2370697C (en) 1999-04-19 2012-03-06 Smithkline Beecham Biologicals S.A. Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide
US6558670B1 (en) 1999-04-19 2003-05-06 Smithkline Beechman Biologicals S.A. Vaccine adjuvants
JP2003501110A (en) 1999-06-10 2003-01-14 ヒューマン ジーノーム サイエンシズ,インコーポレイテッド Streptococcus pneumoniae protein and vaccine
US6319224B1 (en) 1999-08-20 2001-11-20 Bioject Medical Technologies Inc. Intradermal injection system for injecting DNA-based injectables into humans
US6494865B1 (en) 1999-10-14 2002-12-17 Becton Dickinson And Company Intradermal delivery device including a needle assembly
US20040191834A1 (en) * 1999-10-28 2004-09-30 Laferriere Craig Antony Joseph Novel method
WO2001046127A1 (en) 1999-12-22 2001-06-28 Om Pharma Acyl pseudopeptides bearing a functionalised auxiliary spacer
FR2806304B1 (en) * 2000-03-17 2002-05-10 Aventis Pasteur polysaccharide conjugate pneumococcal vaccine use has against tetanus and diphtheria
GB0007432D0 (en) 2000-03-27 2000-05-17 Microbiological Res Authority Proteins for use as carriers in conjugate vaccines
AU7038101A (en) 2000-06-20 2002-01-02 Shire Biochem Inc Streptococcus antigens
EA006313B1 (en) * 2000-06-29 2005-10-27 Глаксосмитклайн Байолоджикалс С.А. Multi-valent immunogenic compositions and methods for using same
WO2002012258A1 (en) 2000-08-04 2002-02-14 Corixa Corporation New immunoeffector compounds
GB0022742D0 (en) * 2000-09-15 2000-11-01 Smithkline Beecham Biolog Vaccine
EP2292632A3 (en) 2000-09-26 2012-07-25 Idera Pharmaceuticals, Inc. Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes
GB0103170D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
WO2002078673A1 (en) 2001-03-29 2002-10-10 Takeda Chemical Industries, Ltd. Process for producing fine granulate drug
US20030031684A1 (en) 2001-03-30 2003-02-13 Corixa Corporation Methods for the production of 3-O-deactivated-4'-monophosphoryl lipid a (3D-MLA)
GB0108364D0 (en) * 2001-04-03 2001-05-23 Glaxosmithkline Biolog Sa Vaccine composition
AU2002309706A1 (en) 2001-05-11 2002-11-25 Aventis Pasteur, Inc. Novel meningitis conjugate vaccine
FR2827199B1 (en) 2001-07-10 2004-07-09 Centre Nat Rech Scient Method and ex situ production machine networks of low and medium integration biochips
GB0123580D0 (en) 2001-10-01 2001-11-21 Glaxosmithkline Biolog Sa Vaccine
WO2003035836A2 (en) 2001-10-24 2003-05-01 Hybridon Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends
GB0130215D0 (en) * 2001-12-18 2002-02-06 Glaxosmithkline Biolog Sa Vaccine
WO2003054007A2 (en) 2001-12-20 2003-07-03 Shire Biochem Inc. Streptococcus antigens
EP1482795B1 (en) 2002-02-04 2009-11-11 Corixa Corporation New immunoeffector compounds
AU2003257003A1 (en) 2002-07-30 2004-02-16 Baxter Healthcare S.A. Chimeric multivalent polysaccharide conjugate vaccines
HUE029200T2 (en) 2002-08-02 2017-03-28 Glaxosmithkline Biologicals Sa Neisserial vaccine compositions comprising a combination of antigens
GB0220198D0 (en) * 2002-08-30 2002-10-09 Chiron Spa Modified saccharides,conjugates thereof and their manufacture
WO2004081515A2 (en) 2003-03-13 2004-09-23 Glaxosmithkline Biologicals S.A. Purification process for bacterial cytolysin
US20060251675A1 (en) 2003-03-17 2006-11-09 Michael Hagen Mutant cholera holotoxin as an adjuvant and an antigen carrier protein
BRPI0411815A (en) 2003-06-23 2006-08-08 Baxter Int y-type neisseria meningitidis vaccines and their meningococcal combinations
US8048432B2 (en) * 2003-08-06 2011-11-01 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Polysaccharide-protein conjugate vaccines
GB0323103D0 (en) * 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
GB0408977D0 (en) * 2004-04-22 2004-05-26 Chiron Srl Immunising against meningococcal serogroup Y using proteins
RU2379052C2 (en) 2004-04-30 2010-01-20 Чирон С.Р.Л. Meningococcal conjugate vaccination
US20080138359A1 (en) 2004-05-11 2008-06-12 Steeghs Liana Juliana Josephin Neisseria meningitidis lgtb Los as Adjuvant
GB0421083D0 (en) 2004-09-22 2004-10-27 Glaxosmithkline Biolog Sa Purification process
GB0502096D0 (en) 2005-02-01 2005-03-09 Chiron Srl Purification of streptococcal capsular polysaccharide
US20070184072A1 (en) 2005-04-08 2007-08-09 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
SI1868645T1 (en) 2005-04-08 2012-04-30 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
US7955605B2 (en) * 2005-04-08 2011-06-07 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
EA012528B1 (en) 2005-06-27 2009-10-30 Глаксосмитклайн Байолоджикалс С.А. Immunogenic composition
MX348734B (en) 2005-09-01 2017-06-27 Novartis Vaccines And Diagnostics Gmbh & Co Kg Multiple vaccination including serogroup c meningococcus.
WO2007053781A2 (en) 2005-11-01 2007-05-10 Novartis Ag Compositions with antigens adsorbed to calcium phosphate
TWI457133B (en) * 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa Novel composition
HUE041979T2 (en) 2005-12-22 2019-06-28 Glaxosmithkline Biologicals Sa Pneumococcal polysaccharide conjugate vaccine
GB0607088D0 (en) * 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
SI2167121T1 (en) 2007-06-26 2015-12-31 Glaxosmithkline Biologicals S.A. Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates
MX346071B (en) 2008-12-18 2017-03-02 Wyeth Llc Method for controlling streptococcus pneumoniae polysaccharide molecular weight using carbon.

Also Published As

Publication number Publication date
PL1973564T3 (en) 2017-04-28
IL211664D0 (en) 2011-05-31
SI3017827T1 (en) 2019-01-31
CN101378779A (en) 2009-03-04
US20160243219A1 (en) 2016-08-25
NO20082646L (en) 2008-09-16
CN101374548A (en) 2009-02-25
CN101378778A (en) 2009-03-04
KR20080081060A (en) 2008-09-05
KR20140036327A (en) 2014-03-25
IL192084D0 (en) 2008-12-29
UA96583C2 (en) 2011-11-25
CN103251940A (en) 2013-08-21
AU2006327036A1 (en) 2007-06-28
CY1118535T1 (en) 2017-07-12
MY147495A (en) 2012-12-14
AU2010241281B2 (en) 2012-12-06
MX354843B (en) 2018-03-22
EA200801344A1 (en) 2008-12-30
CA2634885A1 (en) 2007-06-28
JP2009520759A (en) 2009-05-28
US20090010959A1 (en) 2009-01-08
JO2813B1 (en) 2014-09-15
NO20082647L (en) 2008-09-18
CA2634887C (en) 2016-01-19
MY160199A (en) 2017-02-28
EP3020411A1 (en) 2016-05-18
US20180207262A1 (en) 2018-07-26
JP2009520761A (en) 2009-05-28
KR101441368B1 (en) 2014-09-24
AR058707A1 (en) 2008-02-20
CN103585623A (en) 2014-02-19
US9884113B2 (en) 2018-02-06
BRPI0620460B1 (en) 2019-08-13
AU2006327036B2 (en) 2012-11-15
CN101378779B (en) 2015-09-02
PE20071058A1 (en) 2007-11-27
JP5461838B2 (en) 2014-04-02
CN101374548B (en) 2013-05-01
IL191911D0 (en) 2008-12-29
PL2384765T3 (en) 2017-05-31
PT2384765T (en) 2017-02-06
JP5849125B2 (en) 2016-01-27
PT3017827T (en) 2019-01-28
CA2634885C (en) 2016-04-19
BRPI0620163B1 (en) 2019-08-13
EP1973564B1 (en) 2016-11-09
JP2014205673A (en) 2014-10-30
LT1973564T (en) 2016-12-27
US20100074922A1 (en) 2010-03-25
EP1962899A2 (en) 2008-09-03
EP2382986A2 (en) 2011-11-02
HK1120230A1 (en) 2011-12-09
EA014165B1 (en) 2010-10-29
EP2402025A3 (en) 2012-03-07
CY1116407T1 (en) 2017-02-08
EA200801367A1 (en) 2008-12-30
MA30066B1 (en) 2008-12-01
KR101367237B1 (en) 2014-03-14
CN103585623B (en) 2016-09-28
CY1112677T1 (en) 2016-02-10
CY1118345T1 (en) 2017-06-28
HRP20161681T1 (en) 2017-01-13
AR058592A1 (en) 2008-02-13
EA200801374A1 (en) 2008-12-30
TR201900418T4 (en) 2019-02-21
PE20071305A1 (en) 2007-12-14
EP2384765A2 (en) 2011-11-09
CA2633772C (en) 2015-09-15
PL1962899T3 (en) 2011-12-30
WO2007071710A2 (en) 2007-06-28
MY148141A (en) 2013-03-15
JP2012229228A (en) 2012-11-22
EA014107B1 (en) 2010-10-29
CA2634887A1 (en) 2007-06-28
MY150719A (en) 2014-02-28
EA014649B1 (en) 2010-12-30
NZ569168A (en) 2012-02-24
DK1973564T3 (en) 2017-01-16
DK3017827T3 (en) 2019-02-18
TWI487534B (en) 2015-06-11
CR10122A (en) 2008-08-21
PT1962899E (en) 2011-10-19
EP1968631B1 (en) 2015-04-08
WO2007071711A2 (en) 2007-06-28
ES2630759T3 (en) 2017-08-23
JP5600337B2 (en) 2014-10-01
HUE041979T2 (en) 2019-06-28
CA2808919C (en) 2016-04-19
LT2384765T (en) 2017-01-10
CR10119A (en) 2008-07-29
EP1962899B1 (en) 2011-08-17
HUE032903T2 (en) 2017-11-28
MA30062B1 (en) 2008-12-01
JP2012232985A (en) 2012-11-29
MX2008008140A (en) 2008-09-24
BRPI0620193A2 (en) 2011-11-01
KR101365001B1 (en) 2014-02-21
IL219641A (en) 2017-10-31
PT1973564T (en) 2017-01-24
SG168517A1 (en) 2011-02-28
SI1962899T1 (en) 2011-11-30
DK2384765T3 (en) 2017-01-09
NZ569077A (en) 2011-08-26
US10279033B2 (en) 2019-05-07
AU2006327040B2 (en) 2010-08-19
LT3017827T (en) 2019-01-10
TWI415622B (en) 2013-11-21
NO20082718L (en) 2008-09-16
EP1968631A2 (en) 2008-09-17
UA96934C2 (en) 2011-12-26
DK1962899T3 (en) 2011-10-31
KR20130103831A (en) 2013-09-24
AU2006327040A1 (en) 2007-06-28
HRP20190037T1 (en) 2019-02-22
TW200738258A (en) 2007-10-16
PH12014502544A1 (en) 2015-12-14
BRPI0620163A2 (en) 2011-11-01
PL3017827T3 (en) 2019-04-30
JP2009520760A (en) 2009-05-28
JP5579387B2 (en) 2014-08-27
IL191913A (en) 2012-07-31
JP2012211165A (en) 2012-11-01
WO2007071710A3 (en) 2007-11-29
IL219641D0 (en) 2012-06-28
KR20080081061A (en) 2008-09-05
TWI465248B (en) 2014-12-21
CN110179974A (en) 2019-08-30
AR058706A1 (en) 2008-02-20
ES2614938T3 (en) 2017-06-02
DK1968631T3 (en) 2015-06-15
CA2808919A1 (en) 2007-06-28
HRP20161682T1 (en) 2017-01-27
IL192084A (en) 2013-11-28
US20090017072A1 (en) 2009-01-15
EP3017827B1 (en) 2018-11-07
JP5749689B2 (en) 2015-07-15
EP1973564A2 (en) 2008-10-01
EP3017827A1 (en) 2016-05-11
US20090017059A1 (en) 2009-01-15
WO2007071707A3 (en) 2007-09-13
MA30065B1 (en) 2008-12-01
EP2384765A3 (en) 2012-06-20
EP2402025A2 (en) 2012-01-04
BRPI0620460A2 (en) 2011-11-16
TW200738257A (en) 2007-10-16
WO2007071710A8 (en) 2008-09-04
JP5792920B2 (en) 2015-10-14
CA2816182A1 (en) 2007-06-28
PT1968631E (en) 2015-07-20
EP2382986A3 (en) 2012-08-22
SI1973564T1 (en) 2017-02-28
KR20080081063A (en) 2008-09-05
CA2816182C (en) 2018-02-20
CL2013002106A1 (en) 2014-03-07
CN101378778B (en) 2013-02-06
NO344187B1 (en) 2019-09-30
US20180250389A9 (en) 2018-09-06
ES2539795T3 (en) 2015-07-06
CA2633772A1 (en) 2007-06-28
SI2384765T1 (en) 2017-03-31
KR101418240B1 (en) 2014-07-16
EP2384765B1 (en) 2016-11-23
EP3130348A1 (en) 2017-02-15
NO343981B1 (en) 2019-08-05
AT520415T (en) 2011-09-15
TW201350129A (en) 2013-12-16
US20150190521A1 (en) 2015-07-09
HUE033081T2 (en) 2017-11-28
US9107872B2 (en) 2015-08-18
HRP20110685T1 (en) 2011-10-31
IL191911A (en) 2015-09-24
SI1968631T1 (en) 2015-07-31
ES2707499T3 (en) 2019-04-03
EP3470080A1 (en) 2019-04-17
JP5615323B2 (en) 2014-10-29
US20190262447A1 (en) 2019-08-29
WO2007071707A2 (en) 2007-06-28
AU2006327041A1 (en) 2007-06-28
NZ569076A (en) 2011-08-26
NZ596500A (en) 2013-05-31
AU2010241281A1 (en) 2010-11-25
AU2006327041B2 (en) 2010-08-26
WO2007071711A3 (en) 2007-11-08
US20150265702A1 (en) 2015-09-24

Similar Documents

Publication Publication Date Title
DK1896063T3 (en) immunogenic composition
DK1912671T3 (en) BETA-glucuronide-LINKER-drug conjugates
DK1968631T3 (en) Vaccine
DK2417983T3 (en) Multivalent pneumococcal polysaccharide-protein conjugate composition
EP2170363A4 (en) Tissue specific peptide conjugates and methods
AT525374T (en) Heteroarylsubstituted pyrroloe2,3-büpyridine and pyrroloä2,3-büpyrimidine as januskinaseinhibitors
IL180762D0 (en) Insulin-oligomer conjugates, formulations and uses thereof
DE602005008595D1 (en) Prebiotic preparation
SI2066344T1 (en) Inactivated Poliovirus combination vaccine
AT548051T (en) Multivalent pneumokoken polysaccharid protein conjugate composition
EP1915925A4 (en) Chair
HK1121396A1 (en) Pqs and its conjugates as adjuvants and their uses in pharmaceutical compositions pqs
HK1116085A1 (en) Novel vaccine formulations
GB0411411D0 (en) Vaccines
PL1926496T3 (en) Pcv-2 vaccine
AP201005173A0 (en) Compositions comprising pneumococcal antigens
EP1833375A4 (en) Straight introduction device that assumes curved configuration
PL1968630T3 (en) Multivalent pcv2 immunogenic compositions
HK1090524A1 (en) Anti-pinching folding chair
ZA200703663B (en) Improved PRRS vaccines
SI1957647T1 (en) Immunostimulatory oligoribonucleotides
HK1127486A1 (en) Therapeutic vaccine
PL1861572T3 (en) Furniture
IL220816A (en) Process for preparing cell-binding agent-cytotoxic agent conjugates
RU2007127993A (en) Sugarid conjugate vaccines

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed